TrialBMC cancer2023

The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).

Lucas C Mendez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.